An Activist FDA Could Benefit Drug Development
This article was originally published in RPM Report
Executive Summary
Former FDA Commissioner David Kessler sees a big opportunity for FDA to clarify approval criteria for cancer drugs and personalized medicine projects in the period after the upcoming election. This is time to begin planning for that period of opportunity.